Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals

Bristol Cormorant

July 5, 2016

Bristol-Myers Squibb Company and Cormorant Pharmaceuticals have announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, which is a private, Stockholm, Sweden-based pharmaceutical company that focuses on the development of therapies for cancer and rare diseases. This acquisition allows Bristol-Myers Squibb gain full rights to Cormorant’s HuMax-IL8 antibody program and the lead candidate HuMax-IL8, a Phase 1/2 monoclonal antibody targeted against interleukin-8 (IL-8) representing a potentially complementary immuno-oncology mechanism of action to T-cell directed antibodies and co-stimulatory molecules.

As said by Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, Bristol-Myers Squibb: “We believe combination therapy will be foundational to delivering the potential for long-term survival for patients, and the opportunity to develop the HuMax-IL8 antibody program together with our broad Immuno-Oncology pipeline enables us to accelerate the next wave of potentially transformational immunotherapies.”

“Bristol-Myers Squibb is the ideal company to maximize the potential of both Cormorant and the HuMax-IL8 program, and bring hope to more patients. Bristol-Myers Squibb is the leader in the Immuno-Oncology field, with deep clinical development and regulatory expertise, and an established commercial infrastructure to deliver important new therapies to patients quickly. Bristol-Myers Squibb’s rich pipeline of clinical candidates and approved products provides even more opportunity for potential therapeutic synergy when coupled with HuMax-IL8,” said Maarten de Château, M.D., Ph.D., chief executive officer, Cormorant Pharmaceuticals.

Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals last edit: 2016-07-08T17:18:38+00:00 da Luca

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar